Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 crossover bioavailability and food-effect study of INF904 capsule formulations
NL-OMON59586Phase 1Completed
- Sponsor
- InflaRx
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of izicopan (2 arms), sponsored by InflaRx. Primary endpoint: Primary endpoint(s). Started Jun 2024; status: completed.
02
Drugs
izicopan
Beyond the preview
Go deeper on NL-OMON59586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59586.